FY2025 EPS Estimates for CLDX Lowered by Cantor Fitzgerald

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Investment analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for Celldex Therapeutics in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of ($3.67) for the year, down from their prior forecast of ($3.61). Cantor Fitzgerald has a “Overweight” rating and a $67.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.02. The company had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%.

Other analysts also recently issued research reports about the company. UBS Group started coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday, February 28th. Finally, The Goldman Sachs Group reduced their price target on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $55.38.

Celldex Therapeutics Stock Up 1.1 %

Shares of Celldex Therapeutics stock opened at $21.33 on Thursday. Celldex Therapeutics has a 52 week low of $18.61 and a 52 week high of $49.65. The company has a 50 day moving average price of $23.48 and a 200 day moving average price of $28.59. The firm has a market capitalization of $1.42 billion, a P/E ratio of -8.30 and a beta of 1.76.

Institutional Trading of Celldex Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jennison Associates LLC increased its stake in Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after purchasing an additional 321,325 shares during the last quarter. Values First Advisors Inc. boosted its holdings in shares of Celldex Therapeutics by 20.0% in the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company’s stock worth $733,000 after buying an additional 4,837 shares during the period. BNP Paribas Financial Markets boosted its position in Celldex Therapeutics by 293.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company’s stock worth $958,000 after acquiring an additional 21,013 shares during the period. Bellevue Group AG raised its holdings in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company’s stock worth $104,404,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Celldex Therapeutics during the 3rd quarter valued at about $871,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.